Related references
Note: Only part of the references are listed.Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells
K. English et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Brief Report: Investigation of the Cause of Death in a Gene-Therapy Trial.
Karen M. Frank et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type I diabetic mice
Fernando E. Ezquer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes
Reza Abdi et al.
DIABETES (2008)
Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes
Christian Pfleger et al.
DIABETES (2008)
ransplantation of Bone Marrow-Derived Mesenchymal Stem Cells Improves Diabetic Polyneuropathy in Rats
Taiga Shibata et al.
DIABETES (2008)
Islet Inflammation in Type 2 Diabetes From metabolic stress to therapy
Marc Y. Donath et al.
DIABETES CARE (2008)
Cytokines and β-cell biology:: from concept to clinical translation
Marc Y. Donath et al.
ENDOCRINE REVIEWS (2008)
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia
Nadine S. Sauter et al.
ENDOCRINOLOGY (2008)
Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation
Marianne Boni-Schnetzler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4(+)CD25(high)FOXP3(+) regulatory T cells
Zohair Selmani et al.
STEM CELLS (2008)
Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats
David S. Kwon et al.
INTERNATIONAL WOUND JOURNAL (2008)
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus
Marc Y. Donath et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Opportunities and challenges for mesenchymal stem cell-mediated heart repair
Douwe E. Atsma et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Hnmunomodulatory properties of mesenchymal stromal cells
Alma J. Nauta et al.
BLOOD (2007)
Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing
Giselle Chamberlain et al.
STEM CELLS (2007)
Isolation of multipotent stem cells from mouse adipose tissue
Naoki Yamamoto et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2007)
Increased number of islet-associated macrophages in type 2 diabetes
Jan A. Ehses et al.
DIABETES (2007)
Potential risks of bone marrow cell transplantation into infarcted hearts
Martin Breitbach et al.
BLOOD (2007)
Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury
Luis A. Ortiz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Claus M. Larsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sarcoma derived from cultured mesenchymal stem cells
Jakub Tolar et al.
STEM CELLS (2007)
Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice
Ryang Hwa Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells
Alma J. Nauta et al.
JOURNAL OF IMMUNOLOGY (2006)
Mesenchymal stem cells reside in virtually all post-natal organs and tissues
Lindolfo da Silva Meirelles et al.
JOURNAL OF CELL SCIENCE (2006)
Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice
WN Deng et al.
DNA AND CELL BIOLOGY (2005)
Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway
A Augello et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Adenoviral overexpression of interleukin-1 receptor antagonist protein increases beta-cell replication in rat pancreatic islets
N Tellez et al.
GENE THERAPY (2005)
Regulatory effects of interleukin (IL)-1, interferon-β, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue
CE Juge-Aubry et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Adipose tissue is a major source of interleukin-1 receptor antagonist - Upregulation in obesity and inflammation
CE Juge-Aubry et al.
DIABETES (2003)
Immature, but not inactive: the tolerogenic function of immature dendritic cells
K Mahnke et al.
IMMUNOLOGY AND CELL BIOLOGY (2002)
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
K Maedler et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation by TGF-beta 1 and IL-4
S Perrier et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis
DL Eizirik et al.
DIABETOLOGIA (2001)
Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor
N Giannoukakis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis
R Dewberry et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1
CA Dinarello
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6
R Daig et al.
GUT (2000)